Introduction: Epilepsy is a neurological disorder marked by recurring seizures, and secondary epilepsy refers to seizures that are generated by an underlying medical condition or injury. Low-grade temporal gliomas (LGTGs) frequently have epileptogenic potential, causing seizures. Tumor resection is often the preferred treatment when timing and compatibility with the patient and tumor attributes are determined. Objectives: To discuss the main factors in the medical literature relevant to the improvement of seizures by resection of LGTGs and their surgical features. Methods: A literature review was performed within the PubMed database, using the keywords “low-grade gliomas”, “low-grade tumors”, “resection”, “seizures” and “epilepsy”. Publications from 2010 to 2023 were included. Results: Studies point out that gross full extension resection of LGTGs to achieve seizure freedom results in superior positive outcomes when compared to partial resection for Engel class I patients. Of the patients who had a partial resection, memory deficits were frequent. In addition, recurring epilepsy related to lowgrade tumors and the time span of epilepsy were reported to be higher in children than in adults. Postoperative outcomes of patients with mesial temporal lobe lesions outperformed those with lateral temporal tumors. The addition of hypocampectomy and/or corticectomy of the anterior temporal lobe further improved the seizure freedom rate when compared to gross total lesionectomy. Conclusion: Gross total resection of LGTGs provides a more favorable outcome than partial resection. After surgery, the seizure freedom rate is high (> 70%), and resection type is a significant predictor of seizure recurrence. Subtotal resection has a lower seizure-free rate compared to total lesionectomy, with additional benefits seen from hypocampectomy and/or corticectomy of the anterior temporal lobe. Tumor pathology or laterality did not significantly predict seizure freedom.
The sclerosing mesenteritis (SM) is a rare, non-specific inflammatory condition, mainly affecting the benign intestinal mesentery. It is known that she is diagnosed mainly during the sixth and seventh decade of life and seems to be two times more common in men than in women. The etiology of SM remains unknown, although several mechanisms have been suggested contributors, including surgery or abdominal trauma before, autoimmunity, paraneoplastic syndrome, ischemic injury and infections. The major signs and symptoms are abdominal pain, presence of palpable abdominal mass, nausea and vomiting, bowel changes, weight loss, small bowel obstruction, chylous ascites and peritoneal irritation signals. About of 10% of the patients are asymptomatic. The radiological study, especially computed tomography (CT) and magnetic resonance imaging (MRI) are essential components in the diagnostic evaluation. The ''greasy'' ring signal and the pseudocapsule tomographic findings are considered specific tumoral this pathology. The diagnosis is established by histopathologic study. There is no specific treatment for SM and should this be empirical and individualized. Although they are described cases of spontaneous remission, some authors have shown benefit with the empirical treatment using corticosteroids, colchicine, immunosuppressants, antibiotics, tamoxifen, alone or in combination. The surgical approach has a limited role and usually aimed at symptomatic relief. In most cases, the prognosis is favorable.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.